Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Electronic Reminder Systems for HCV Screening

J Viral Hepat; ePub 2018 Feb 25; MacLean, et al

There was an increase in quantity of patients tested for hepatitis C virus (HCV) following implementation of an electronic reminder system in a primary care setting, a recent study found. The retrospective cohort study sought to 1) determine the effect of the Centers for Disease Control and Prevention (CDC) recommendation for HCV screening for the population born between 1946-1965; 2) the yield of positive HCV tests as screening strategies have evolved, and according to a patient’s history of serum aminotransferase testing; and 3) the proportion of positive cases followed-up for HCV treatment. Researchers found:

  • The study included 60,000 primary care patients serving an urban and rural population in which an EMR reminder was instituted in 2014.
  • There was an increase in proportion tested for HCV from 12% prior to the CDC recommendation to 37% after the reminder system.
  • The yield of positive HCV antibody tests decreased from 7% to 1.6% after the EMR reminder prompted screening of a lower risk population.
  • Patients with a history of abnormal aminotransferase tests had a 5-fold higher rate of positive HCV Ab testing.

Citation:

MacLean CD, Berger C, Cangiano ML, Ziegelman D, Lidofsky SD. Impact of electronic reminder systems on hepatitis C screening in primary care. [Published online ahead of print February 25, 2018]. J Viral Hepat. doi:10.1111/jvh.12885.

This Week's Must Reads

Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al

Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al

Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al

Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al

Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al

Must Reads in Hepatitis

Glecaprevir/pibrentasvir Can Reduce HCV Tx Duration, Hepatol Int; ePub 2018 May 29; Abutaleb, et al

Estimates of HCV by Race and Sex in US, BMC Infect Dis; ePub 2018 May 16; Hall, et al

Efficacy of DAA Therapy for HCV in Older Adults, J Am Geriatr Soc; ePub 2018 May 25; Mazzarelli, et al

HCV Treatment in People Who Inject Drugs, Open Forum Infect Dis; ePub 2018 May 23; Alimohammadi, et al

Risk of HCV Among Vulnerable Populations, J Viral Hepat; ePub 2018 May 31; Aisyah, et al